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Summary 
Objective: Limited evidence supports the use of free testosterone (FT) for diagnosing 
hypogonadism when sex hormone binding globulin (SHBG) is altered. Low total testosterone 
(TT) is commonly encountered in obesity where SHBG is typically decreased. We aimed to 
assess the contribution of FT in improving the diagnosis of symptomatic secondary 
hypogonadism (SH), identified initially by low total testosterone (TT), and then further 
differentiated by normal FT (LNSH) or low FT (LLSH). 
 
Design: Prospective observational study with a median follow-up of 4.3 years. 
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Patients: 3369 community-dwelling men aged 40-79 years from eight European centres. 
 
Measurements: Subjects were categorised according to baseline and follow-up biochemical 
status into persistent eugonadal (referent group; n=1880), incident LNSH (eugonadism to 
LNSH; n=101) and incident LLSH (eugonadism to LLSH; n=38). Predictors and clinical 
features associated with the transition from eugonadism to LNSH or LLSH were assessed. 
 
Results: The cumulative incidence of LNSH and LLSH over 4.3 years was 4.9% and 1.9% 
respectively. Baseline obesity predicted both LNSH and LLSH but the former occurred more 
frequently in younger men. LLSH, but not LNSH, was associated with new/worsened sexual 
symptoms, including low desire [OR= 2.67 (1.27-5.60)], erectile dysfunction [OR= 4.53 (2.05-
10.01)] and infrequent morning erections [OR= 3.40 (1.48-7.84)]. 
 
Conclusions: These longitudinal data demonstrate the importance of FT in the diagnosis of 
hypogonadism in obese men with low TT and SHBG. The concurrent fall in TT and FT 
identifies the minority (27.3%) of men with hypogonadal symptoms, which were not present 
in the majority developing low TT with normal FT. 
 
Keywords: Free testosterone, total testosterone, secondary hypogonadism, obesity, sexual 
symptoms, androgen deficiency, sex hormone binding globulin 
 
Introduction 
According to the “free hormone hypothesis”, the biological activity of hormones is assigned 
to the fraction that is not bound to plasma proteins1. This would imply that the total hormone 
concentration may not always provide an accurate readout of hormone activity, particularly in 
the presence of altered binding protein concentrations. Although widely accepted in 
endocrinology, the “free hormone hypothesis” still lacks robust experimental proof. Recently, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
support for this hypothesis for sex hormones has been provided using a transgenic mouse 
model over-expressing the human sex hormone binding globulin (SHBG)2. As compared to 
wild-type controls, SHBG-transgenic animals had similar free T (FT) levels, but significantly 
higher total testosterone (TT) and luteinising hormone (LH)2. Despite the high TT, these 
animals displayed features consistent with mild androgen-deficiency2, thus supporting the 
view that TT does not accurately reflect androgen status in the presence of SHBG 
abnormalities. Compelling support for the free hormone hypothesis also comes from patients 
with naturally occurring mutations in the SHBG gene. In a young man who carried a 
missense mutation in SHBG gene resulting in extremely low/undetectable levels of SHBG3, 
TT was very low whereas FT and LH were normal. Despite this, sexual development, 
secondary sexual characteristics and semen parameters were normal. Conversely, women 
with normal T and very low SHBG, due to SHBG gene mutations, were reported to have 
features of hyperandrogenism4,5. 
 
The relative roles of TT and FT in the assessment of androgen deficiency have not been 
extensively investigated. At present, the diagnosis of androgen deficiency in symptomatic 
men relies largely on TT6,7. The use of FT is tentatively limited to symptomatic men with 
borderline TT and/or conditions known to affect SHBG6,7, a recommendation based more on 
expert opinion than hard data. There is an urgent need for more and better clinical and 
experimental evidence to assess the role of FT as an independent biomarker of androgen 
function. Recently a cross-sectional analysis of the European Male Ageing Study (EMAS), 
reported a higher probability of androgen deficiency symptoms in men with low FT and low 
TT but not in men with normal FT and low TT8. This strongly supports the view that 
documenting low FT (in addition to low TT) can improve the accuracy of diagnosing 
symptomatic hypogonadism.  
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In a prospective analysis of the EMAS9, we showed that obese eugonadal men are at 
increased risks for developing biochemical secondary hypogonadism (SH) with a 
concomitant deterioration in sexual function compatible with symptomatic androgen 
deficiency. However, SH was defined according to TT and it is unclear whether lower SHBG 
may have contributed to the observed decline in TT (without a concomitant fall in FT), 
thereby potentially inflating the incidence/diagnosis of SH in obese men10. 
 
We hypothesise that the addition of FT to TT in the categorisation of SH can improve the 
precision in identifying men who develop not only biochemical SH but also accompanying 
features of androgen deficiency. Hence, the aim of the present study is to compare and 
contrast the natural history and clinical characteristics of developing SH as defined by low 
TT with low FT and low TT but normal FT.  
 
Materials and Methods 
Participants and study design 
The study design and methods of the EMAS have been previously described extensively11,12. 
Briefly, EMAS is a multicentre, prospective, population-based survey on an age-stratified 
sample of 3369 unselected community-dwelling men aged 40-79 years (mean ± standard 
deviation 60±11) recruited from population registers in eight European centres: Manchester 
(United Kingdom), Leuven (Belgium), Malmö (Sweden), Tartu (Estonia), Lodz (Poland), 
Szeged (Hungary), Florence (Italy) and Santiago de Compostela (Spain). Participants were 
invited to attend the local research clinic for baseline and follow-up (after a median of 4.3 
years; range 3.0-5.7) assessments11,12. During this period, 193 men died and 440 were lost 
to follow-up. At both baseline and follow-up, all participants completed questionnaires 
dealing with degree of education, smoking habits, alcohol intake and currently treated 
illnesses11,12. Moreover, they completed the EMAS Sexual Function Questionnaire, the 
Medical Outcomes Study 36-item Short-Form health survey and the Beck Depression 
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Inventory dealing with sexual, physical and psychological health, respectively. Based on 
previous data from EMAS13, three sexual (erectile dysfunction, decrease in sexual thoughts 
and decreased morning erections), physical (decreased vigorous activity, limited walking and 
decreased bending) and psychological symptoms (fatigue, loss of energy and sadness) were 
considered as the most informative for androgen deficiency. Presence/absence of symptoms 
at baseline or follow-up was defined according to previously identified thresholds13. The 
change in symptoms was evaluated as development/worsening (symptom absent at 
baseline and present at follow-up or present at baseline but with a lower severity grading 
than at follow-up)9,14. Anthropometric measurements, Reuben’s physical performance test, 
and psychomotor processing speed (digit symbol substitution test) were performed at 
baseline and follow-up according to standardised methods11,12. Ethical approval was 
obtained according to local regulations in each centre. All men provided a written informed 
consent. 
 
Hormone measurements 
Single fasting morning (before 10:00 AM) venous blood samples were obtained at baseline 
and follow-up. T was measured by liquid chromatography-tandem mass spectrometry (LC-
MS/MS), with paired baseline and follow-up samples analysed simultaneously. LH and 
SHBG were measured by the E170 platform electrochemiluminescence immunoassay 
(Roche Diagnostics). FT was calculated using the Vermeulen formula15. Intra- and 
interassay coefficients of variation (CVs) were 4.0% and 5.6% for T, 1.7 and 3.2% for SHBG 
and 1.9 and 3.0% for LH. The lower limit of TT measurement was 0.17 nmol/L (0.05 ng/mL). 
Insulin was measured by chemiluminescence (CVs 3.9 and 5.0%). Insulin resistance was 
estimated by the homeostasis model assessment of insulin resistance (HOMA-IR) as 
calculated by 
        
  
 
          
    
 
 
    
. Biochemistry and haematology parameters were 
assessed by standardised methods in hospital laboratories in each centre. 
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Gonadal status 
In keeping with previous EMAS classifications9,14,16, eugonadism was defined as TT≥10.5 
nmol/L and secondary hypogonadism (SH) as TT<10.5 nmol/L and LH≤9.4 U/L. In the 
present analysis, SH was further subdivided, according to FT levels, into normal FT (≥170 
pmol/L) with low TT (Low TT and Normal FT: LNSH) and low FT (<170 pmol/L) with low TT 
(Low TT and Low FT: LLSH). Men in the analytical sample were categorised on the basis of 
TT into two main groups, according to their change in gonadal status: 1) persistent 
eugonadism (PE; eugonadism at baseline and follow-up; referent group) and 2) incident SH 
(eugonadism at baseline and SH at follow-up). The second group was further subdivided 
according to gonadal status at follow-up (incident LNSH or LLSH). The group of men (n = 30 
at baseline and n = 2 at follow-up) with normal TT but low FT was not included in the 
analysis because the research question was aimed at assessing the relevance of introducing 
FT to the previous definition of SH based on low TT9.  
 
Since a validated reference range for FT is lacking17, we conducted exploratory analyses on 
our sample in order to identify an appropriate FT threshold. We modelled logistic regressions 
using incident low FT as the independent variable (with persistent normal FT as referent 
group) to predict the development/worsening of androgen deficiency symptoms9,14. The 
definitions of incident low FT were based on FT values only (without reference to TT) and 
were constructed using various putative thresholds by the stepwise decline of FT (by 10 
pmol/L) below 250 pmol/L. FT values of 180 and 170 pmol/L emerged as the best predictors 
of worsening erectile dysfunction and decreased morning erection (Supplementary Figure 1). 
This accorded with the lower reference limit of FT of 170 pmol/L suggested by the Endocrine 
Society guidelines of 201018 based on results from several commercial laboratories 
measuring FT by equilibrium dialysis. In addition, it confirmed our previous cross-sectional 
analyses13. We therefore selected the FT threshold of 170 pmol/L for constructing the 
operational definition of SH in the present analyses. 
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Statistical analysis 
The differences between the analytical groups were initially assessed by the analysis of 
variance and chi-squared tests for continuous and categorical variables, respectively. Post 
hoc analyses were performed using the Tukey–Kramer test and Z-test with correction for 
multiple pairwise comparisons. Multilevel binary logistic regression models were used to 
assess the associations between nine putative predictors9,14 and changes in gonadal status 
(transition from eugonadism to SH) as outcomes, with PE being the referent category. The 
relationship between change in gonadal status and change in clinical features of 
hypogonadism was assessed by binary logistic regression models with nine putative 
symptoms of hypogonadism as outcomes9,14. Results from logistic regressions are 
presented as odds ratios (ORs) and 95% confidence intervals (CIs). With respect to the 
recovery from LNSH and LLSH to eugonadism, the small sample size allowed only the 
assessment and comparison of recovery rates. All statistical analyses were conducted using 
Stata SE 13.1 (StataCorp, College station, TX, USA). A p-value <0.05 was considered as 
significant.  
 
Results 
Gonadal status transition 
Figure 1 describes the derivation of the analytical sample from the initial population of 3369 
EMAS participants. After excluding those who died (n=193) or were lost to follow-up (n=440), 
a further 132 and 162 men, with diagnosed pituitary, testicular or adrenal diseases or use of 
medications known to affect the hypothalamic-pituitary-gonadal axis at baseline and follow-
up, were excluded. Gonadal status at baseline or follow-up could not be defined due to 
missing data in 121 men. A further 53 and 32 men were excluded because of biochemical 
primary hypogonadism or normal TT but low FT respectively, at baseline or follow-up (Figure 
1). This provided 2236 eligible men in the analytical sample, their differences from those who 
died or were lost to follow-up are shown in Supplementary Table 1. 2019 eugonadal men at 
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baseline were included in the analytical sample for capturing progression to SH, while 217 
men who already had SH at baseline were considered only for describing recovery rates. 
 
Of the 2019 EUG men at baseline, 1880 were classified as PE at follow-up, 139 developed 
SH, of whom 101 (72.7%) had FT≥170 pmol/L (LNSH) and 38 (27.3%) had FT<170 pmol/L 
(LLSH) (Figure 1). Incidence for LNSH and LLSH was 4.9% and 1.9% respectively over 4.3 
years. Assuming linearity of transition, this translates to an LNSH incidence rate of 114.5 per 
10,000 per year, or 1.1% per annum and for an LLSH incidence rate of 43.1 per 10,000 per 
year, or 0.4% per annum. 
 
Characteristics of the analytical groups 
Incident LNSH men were younger than incident LLSH subjects (Table 1). No differences in 
education level, marital status, smoking habits and alcohol intake at baseline and follow-up 
were found between the three groups (Table 1).  
 
Hormone levels 
At baseline, by definition, all men had TT and FT within the normal range, although their 
levels were already significantly lower in incident LNSH and LLSH than in PE (Table 1). 
SHBG at baseline was the lowest in incident LNSH, whereas incident LLSH had 
intermediate levels and PE men had the highest (Table 1). At follow-up, the differences in 
SHBG between the three groups followed those found at baseline. SHBG had different 
trends over time in the three groups, being significantly increased in PE, decreased in 
incident LNSH and unchanged in incident LLSH. 
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Anthropometrics and metabolic parameters 
At baseline, both incident LNSH and LLSH men had significantly greater BMI, waist 
circumference (WC) and body weight than PE subjects (Table 1). At follow-up, the 
differences in BMI and WC between PE and both the incident SH groups were even greater. 
Incident LNSH was characterised at baseline by higher triglycerides than PE, whereas 
incident LLSH had lower HDL-cholesterol and higher HOMA-IR than PE, with a trend 
towards higher fasting glucose (Table 1). At follow-up, the metabolic pattern of incident 
LNSH men significantly worsened, with higher fasting glucose and HOMA-IR and 
triglycerides as well as lower HDL-cholesterol compared to PE. In contrast, incident LLSH 
men maintained their metabolic profile largely unchanged (Table 1). Both the SH groups 
showed a higher prevalence of cardiovascular diseases (CVDs) than PE, particularly at 
follow-up (Table 1). 
 
Predictors of incident LNSH 
Multiple logistic regression analysis showed that overweight and obesity at baseline were 
both significant risk factors for transition from eugonadism to LNSH (OR=2.12[1.06-4.22], 
p=0.033 and 4.18[2.00-8.71], p<0.001 respectively) (Table 2). Younger age was a further 
significant predisposing factor (OR=3.24[1.40-7.47], p=0.006) for LNSH. Substituting waist 
circumference (WC) for BMI confirmed the association with LNSH (OR=2.66[1.36-5.22], 
p=0.004 and 4.48[2.35-8.55], p<0.001 for WC 94-102 and >102 cm, respectively). 
 
Predictors of incident LLSH  
Obesity (Table 2) and WC≥102 cm significantly predicted the development of LLSH 
(OR=5.85 [1.86-18.37], p=0.003 and OR=3.36[1.26-9.01], p=0.016 respectively).  
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Symptoms associated with incident LNSH 
There was no difference in sexual, physical or psychological symptoms between incident 
LNSH and PE men (Table 1) at baseline or follow-up. This was confirmed after adjusting for 
confounders (age, centre, BMI, comorbidity and smoking) (Figure 2). Accordingly, there was 
also no difference in the change (development/worsening) of symptoms during follow-up.  
 
Symptoms associated with incident LLSH 
At baseline, prevalence of symptoms was not different between incident LLSH and PE men 
before (Table 1) and after adjustment for confounders (Figure 2). However, at follow-up, 
incident LLSH men reported all three sexual symptoms (erectile dysfunction, decrease in 
sexual thoughts and decreased morning erections) more frequently. Accordingly, 
development/worsening of sexual symptoms also occurred more frequently in incident LLSH 
men. Lack of vigour was found also to be increased over time in incident LLSH but this 
attenuated after adjustment for comorbidity and smoking (Supplementary Table 2). No other 
associations between LLSH and physical or psychological symptoms were found (Figure 2).  
 
Recovery from LNSH or LLSH 
Of the 224 men with prevalent SH at baseline, 173 (77.2%) were LNSH and 51 (22.8%) 
LLSH (Table 3). Recovery from LNSH to eugonadism during 4.3 years occurred in 46.2% 
men (80/173), which gives a recovery rate of 10.8% per annum, assuming linearity of 
transition. Recovery from LLSH to eugonadism was significantly less frequent (27.5%, 14/51; 
p=0.017 vs. recovery from LNSH), with a recovery rate of 6.4% per annum. 
Analyses on possible predictors or clinical correlates of recovery from LNSH or LLSH did not 
yield meaningful information due to the small sample size. 
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Discussion 
In a previous longitudinal analysis of the EMAS population, we found increased sexual 
symptoms in men who developed SH as defined by the decline in TT9. We have also shown 
previously, in a cross-sectional analysis of the entire EMAS cohort, that adding FT to TT 
yielded stronger associations with clinical feature of androgen deficiency than TT alone, 
which can be influenced by variations in SHBG8. Using subnormal TT alone may therefore 
over-diagnose SH in obese men with low SHBG, when FT can remain normal. The present 
evaluation shows that most men (72.7%) developing apparent biochemical SH, as defined 
by low TT, in fact had normal FT levels (LNSH), whereas low FT (LLSH) was found only in a 
minority of these men (27.3%). Men with LNSH and LLSH have clear differences in clinical 
characteristics. The most important is that sexual symptoms are associated only with the 
development of LLSH, but not with LNSH. Despite different clinical pictures, both LLSH and 
LNSH are predicted by obesity. This confirms our previous results showing adiposity as the 
most important predisposing factor for development of SH9. In the present analysis, we were 
able to show additionally that LNSH typically develops in younger men, whereas age is not a 
significant predictor for the development of LLSH. Furthermore, a different natural history 
was revealed, with a significantly higher proportion of men recovering to eugonadism in 
LNSH than LLSH (46.2% vs. 27.5%, p=0.017) over 4.3 years. 
 
Since sexual symptoms are considered the cardinal features of adult hypogonadism13,19, our 
findings indicate that low FT, in combination with low TT, provides the best discriminatory 
metric for detecting androgen deficiency. Furthermore, the association with sexual 
symptoms suggests that LLSH only should be regarded as a genuine form of hypogonadism. 
In contrast, the clinical features associated with the development of LNSH are 
indistinguishable from that of PE, suggesting that it is a specious biochemical state 
(reflecting low SHBG) rather than true hypogonadism. The present prospective data confirm 
and extend our previous cross-sectional results8 showing that androgen deficiency features 
are most commonly encountered when both TT and FT are low, highlighting the potential 
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pitfall of mis-diagnosing SH in obese men which can be avoided by the addition of FT. Given 
that our previous cross-sectional results provided the only available evidence showing the 
importance of FT in the diagnosis of hypogonadism to date17, the new longitudinal data 
presented here furnish important additional evidence to support the use of FT when 
evaluating the gonadal status in conditions of altered SHBG, such as in obesity. 
 
The present findings have wider clinical relevance in the context of the huge increase in the 
number of testosterone prescriptions worldwide (particularly in North America) over the last 
two decades20. Our data suggest that genuine symptomatic hypogonadism associated with 
obesity has a relatively low prevalence and incidence in the general population in Europe, 
and may well also be the case in North America, thus suggesting that only a small proportion 
of obese men presenting with low TT would merit T therapy. Instead, it can be inferred that 
weight-reducing lifestyle measures may represent the most appropriate management to 
promote recovery to eugonadism in obese patients with borderline-low TT levels. Previous 
longitudinal data from the EMAS21 have shown that 10-15% weight loss over 4.3 years was 
associated with an increase in both TT and FT, together with LH, thus suggesting recovery 
of hypothalamus-pituitary-testis (HPT) axis function. Similar results were observed in the 
meta-analysis of clinical trials, which evaluated hormone changes upon managed intentional 
weight loss22, where both diet and bariatric surgery were able to reverse obesity-related SH 
with an improvement directly proportional to the extent of weight loss. It should be also noted 
that, in the present study, a high recovery rate (46.2%) to eugonadism was observed among 
younger obese men with LNSH. This suggests that symptomatic young obese men with low 
TT levels should be cautiously evaluated with repeated hormone testing (preferably after 
losing weight) before a final diagnosis of hypogonadism is established. 
 
Obesity, especially when severe, can be associated with SH, characterised by low/normal 
LH and low FT despite the low SHBG10. The mechanisms involved in gonadotrophin 
suppression are complex and poorly understood. These may include central leptin- and 
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insulin-resistance as well as the inhibitory effect of pro-inflammatory cytokines on 
KNDY/GnRH neurons, which can impair directly or indirectly the HPT axis23–25. The 
hypothesised role of oestradiol excess in enhancing the negative feedback on HPT axis is 
controversial16,26. Indeed, the putative increase of aromatase activity due to the expanded 
adipose tissue is not supported by data from our16 and other studies27, which show that 
oestradiol, concurrently with T decline, is lower rather than higher, in obese men. There is 
also some evidence from in vitro studies that testicular steroidogenesis can be directly 
affected by adipocytokines, including leptin, TNF-α and decreased adiponectin28,29. The 
mechanisms leading to the reduction in SHBG observed in obese men are also debated. 
Hyperinsulinemia and hyperglycaemia have been shown to inhibit SHBG synthesis by 
hepatocytes30,31. Recent studies indicated that SHBG can be also down regulated by TNFα 
and IL1β and up regulated by adiponectin32–34; these mechanisms, arising from low grade 
chronic inflammation, may contribute to the lower serum SHBG associated with obesity 
. 
Strength and limitations 
The main strengths of this study are the large sample of men representative of the European 
general population and the longitudinal design, which is less affected by confounders than 
cross-sectional studies. The relatively small size of some of the analytical groups reflects the 
low incidence of hypogonadism in the general population, which may have been inflated by 
less rigorous studies. Another strength is the use of standardised instruments throughout the 
EMAS centres and at both study phases. Testosterone was measured by LC-MS/MS, with 
baseline and follow-up samples analysed simultaneously representing a further strength. 
However, some limitations should be acknowledged. As in previous EMAS published 
reports, FT was calculated, rather than directly measured in the present study. Although 
equilibrium dialysis is considered the most reliable and accurate determination for FT, it is 
impractical for an epidemiological study of this scale. Using the Vermeulen formula15, which 
has been well-validated against directly measured FT35, our results, based on internal 
comparisons of the same subjects over time, should not be affected by any potential 
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differences between alternative methods for calculating FT.  By using the Vermeulen 
formula, the most commonly used algorithm in hospital clinical biochemistry laboratories and 
in clinical practice, to derive calculated FT in this study, our results are potentially more 
generalizable to real life clinical practice. The study interval of a median of 4.3 years may be 
relatively short for observing spontaneous changes in hormones and unfolding of clinical 
characteristics over time. A single measurement at each time point was available for TT and 
LH. Although important for individual patient diagnosis in clinical practice, multiple blood 
sample collection is impractical in large population-based epidemiological surveys36,37. In this 
regard, T has been confirmed as a stable analyte without significant fluctuation within the 
same subject when measured serially over many months38–41. Furthermore, the consistency 
of TT and LH levels between baseline and follow-up (respectively r=0.764 and 0.794, both 
p<0.001) and the agreement between LH and FSH (r=0.695 and 0.766, both p<0.01 
respectively at baseline and follow-up) adds credence to our results, making it unlikely that a 
single hormone determination would have introduced substantial misclassification of gonadal 
status.  
 
Conclusion 
These prospective data show that a subgroup of obese men characterised by low TT and 
low FT are prone to develop multiple sexual symptoms suggestive of androgen deficiency, in 
contrast to the majority of obese men with low TT (and low SHBG) but normal FT, who do 
not develop symptoms of hypogonadism. The latter group, which frequently remits 
spontaneously to eugonadism, is often incorrectly diagnosed to have (and treated for) 
hypogonadism. The use of FT in obesity can contribute to clinical practice by preventing the 
over-diagnosis of hypogonadism and minimising inappropriate testosterone treatment. 
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Figure legends: 
Figure 1. Flowchart showing derivation during follow-up and distribution of study 
sample by gonadal status and exclusions.  
Footnote: *29 men missing from the original PE group (reference #9) due to normal TT and 
low FT at baseline or at follow-up, **1 men missing from the original incident SH group 
(reference #9  due to normal TT and low FT at baseline, † 2 missing men from the original 
recovery from SH group (reference #9) due to normal TT and low FT at follow-up. ‡ 32 men 
with normal TT and low FT at baseline or at follow-up accounts for the men missing from the 
previously studied analytical group (reference #9), as reported above. 
Abbreviations: LH, luteinising hormone; TT, total testosterone; FT, free testosterone; PE, 
persistent eugonadism; SH, secondary hypogonadism; LNSH, low total testosterone/normal 
free testosterone secondary hypogonadism; LLSH, low total testosterone/low free 
testosterone secondary hypogonadism.  
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Figure 2: Figure 2. Relationship between change in gonadal status and clinical 
symptoms. 
Footnote: Logistic regression analysis of clinical symptoms (outcome variables) in relation to 
incident SH groups using persistent eugonadism as referent. Adjustments were made for 
BMI, age, comorbidity burden (≥1 comorbidities , centre and smoking.  ata are expressed 
as odds ratio ±95% confidence interval. The black, white and grey symbols denote the 
relation between incident SH and respectively the symptoms at baseline, at follow-up and 
their change (worsening/development) over time during follow-up. Level of statistical 
significance is denoted by: * = p <0.05, ** = p <0.01 and *** = p <0.001. 
Abbreviations: SH, secondary hypogonadism; LNSH, low total testosterone/normal free 
testosterone secondary hypogonadism; LLSH, low total testosterone/low free testosterone 
secondary hypogonadism, BMI, Body Mass Index.  
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Table 1. Baseline and Follow-Up Characteristics of Men with Persistent Eugonadism 
(PE), those with Incident Secondary Hypogonadism with low total and normal free 
testosterone (LNSH) and those with Incident Secondary Hypogonadism with both low 
total and low free testosterone (LLSH) 
 Baseline  Follow-Up  
Parameter PE Incident 
LNSH 
Incident 
LLSH 
P
1
 PE Incident 
LNSH 
Incident LLSH P
2
 
Sample size 
(N) 
1,880 101 38  1,880 101 38  
Age, years 
58.1 
±10.4 
55.7 
±10.3 
60.6 
±9.4
b
 
0.025 --- --- --- --- 
Pre-degree 
Education
3
, n 
(%) 
1291 
(70.2) 
74 
(77.1) 
28 
(73.7) 
0.323 --- --- --- --- 
Living with 
partner, n(%) 
1610 
(87.5) 
83 
(86.5) 
33 
(86.8) 
0.950 1491 (85.0) 80 (86.0) 30 (79.0) 0.564 
Smoking, n 
(%) 
383 
(20.6) 
18 
(17.8) 
6 (16.2) 0.658 331 (18.2)*** 8 (8.6) 6 (16.7) 0.060 
Frequent 
Alcohol, n (%) 
470 
(25.1) 
22 
(21.8) 
7 (18.4) 0.493 579 (35.5)*** 29 (36.3)** 12 (38.7)* 0.924 
Poor health, n 
(%) 
375 
(20.1) 
22 
(22.0) 
10 
(27.0) 
0.537 424 (23.4)*** 23 (24.5) 15 (39.5) 0.070 
≥1 illness, n 
(%) 
705 
(37.5) 
46 
(45.5) 
18 
(47.4) 
0.132 984 (52.3)*** 68 (67.3)***
a
 30 (79.0)**
a
 <.001 
≥2 illnesses, n 
(%) 
275 
(19.0) 
11 
(16.7) 
8 (28.6) 0.387 532 (37.3)*** 30 (47.6)** 16 (66.7) 0.004 
Diabetes, n 
(%) 
95 
(5.1) 
5 (5.0) 2 (5.4) 0.947 116 (6.4)*** 8 (8.5) 6 (15.8) 0.052 
CVD, n (%) 
553 
(29.8) 
35 
(35.0) 
16 
(42.1) 
0.155 710 (40.1)*** 51 (54.8)***
a
 23 (63.9)
a
 <.001 
Cancer, n (%) 
81 
(4.3) 
6 (5.9) 
6 
(15.8)
a
 
0.003 149 (8.4)*** 9 (9.7) 11 (29.0)
ab
 <.001 
Prostate 
disease, n (%) 
164 
(8.9) 
4 (4.0) 2 (5.4) 0.203 181 (10.0)* 3 (3.2) 5 (13.5) 0.039 
Overall Sexual 
Function 
22.2 
±6.5 
23.1 
±6.4 
19.9 
±6.9 
0.073 21.4 ±6.8*** 21.3 ±6.8** 16.2 ±7.9**
ab
 <.001 
SF-36 
physical 
51.2 
±7.5 
51.8 
±7.6 
51.9 
±8.0 
0.609 50.6 ±8.1** 49.8 ±8.9** 48.0 ±10.1* 0.128 
Beck’s 
Depression 
Inventory 
6.3 
±5.9 
6.1 
±5.5 
7.3 
±6.4 
0.550 6.2 ±6.3 5.5 ±5.8 8.2 ±7.7 0.090 
SF-36 mental 
52.1 
±8.6 
53.2 
±7.4 
52.5 
±9.4 
0.438 52.0 ±9.1 52.9 ±7.8 50.2 ±10.2 0.328 
DSST 
29.0 
±8.3 
29.4 
±8.8 
28.5 
±8.3 
0.827 28.1 ±8.9*** 28.2 ±9.8** 25.1 ±9.9** 0.113 
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PASE score 
208.1 
±87.5 
200.0 
±82.9 
200.3 
±103.1 
0.611 
183.8 
±93.8*** 
162.4 ±93.7** 182.3 ±103.3 0.101 
50-ft walk, sec 
13.0 
±2.7 
12.8 
±2.2 
13.2 
±2.2 
0.707 13.7 ±2.8*** 13.8 ±2.6*** 14.1 ±2.9* 0.719 
PPT rating 
24.3 
±2.4 
24.7 
±2.4 
24.2 
±2.4 
0.339 23.8 ±2.5*** 23.4 ±2.5*** 23.2 ±3.1* 0.149 
Weight, kg  
82.5 
±13.1 
87.6 
±12.9
a
 
90.5 
±15.4
a
 
<.001 82.4 ±13.4 90.2 ±16.0**
a
 92.5 ±18.4
a
 <.001 
BMI, kg/m
2
 
27.1 
±3.8 
29.0 
±3.7
a
 
29.7 
±4.3
a
 
<.001 27.2 ±3.9*** 30.1 ±4.5***
a
 30.7 ±5.3*
a
 <.001 
Waist 
circumference, 
cm 
96.7 
±10.4 
101.6 
±8.1
a
 
103.3 
±12.5
a
 
<.001 98.0 ±10.8*** 
105.0 
±11.9***
a
 
106.1 ±14.9*
a
 <.001 
FPG 
5.5 
±1.0 
5.5 
±0.8 
5.9 
±0.9 
0.055 5.5 ±1.3 5.8 ±1.5*
a
 5.7 ±1.1 0.032 
HOMA-IR 
2.8 
±3.6 
3.3 
±3.0 
4.3 
±5.7
a
 
0.012 2.8 ±3.0 4.1 ±4.8*
a
 4.4 ±3.4
a
 <.001 
Total 
cholesterol, 
mmol/L 
5.6 
±1.0 
5.8 
±1.1 
5.6 
±1.1 
0.158 5.3 ±1.0*** 5.2 ±1.1*** 4.8 ±1.2***
a
 0.029 
HDL-
cholesterol, 
mmol/L 
1.4 
±0.3 
1.4 
±0.5 
1.3 
±0.3
a
 
0.010 1.4 ±0.4*** 1.2 ±0.4*
a
 1.3 ±0.4 <.001 
LDL-
cholesterol, 
mmol/L 
3.5 
±0.9 
3.6 
±0.9 
3.7 
±1.0 
0.265 3.3 ±1.0*** 3.1 ±1.1** 3.0 ±1.1** 0.067 
Triglycerides, 
mmol/L 
1.5 
±1.1 
1.9 
±1.2
a
 
1.5 
±0.9 
0.001 1.5 ±1.9 2.0 ±1.6
a
 1.5 ±1.0 0.024 
PSA, ng/ml 
1.6 
±2.3 
1.4 
±1.7 
3.4 
±7.7
ab
 
<.001 2.2 ±7.0*** 1.8 ±2.4** 1.3 ±1.1 0.649 
PSA >10 
ng/mL, n(%) 
20 
(1.1) 
1 (1.0) 2 (5.3)a 0.128 35 (1.9) 3 (3.0) 0 (0.0) 0.706 
PSA after 
exclusion of 
values >10 
ng/ml 
1.4±1.4 1.3±1.2 1.4±1.3 0.736 1.6±1.6*** 1.5±1.2*** 1.3±1.1 0.264 
Hb, g/L 
150.4 
±10.4 
150.4 
±10.0 
147.1 
±9.0 
0.157 150.2 ±11.4 148.0 ±10.8 143.3 ±15.5
a
 0.001 
Total T, 
nmol/L 
18.4 
±5.5 
12.6 
±1.9
a
 
13.2 
±2.3
a
 
<.001 18.1 ±5.4** 9.3 ±0.9***
a
 7.5 ±2.5***
a
 <.001 
Free T, pmol/L 
323.7 
±79.3 
279.5 
±45.6
a
 
255.8 
±47.6
a
 
<.001 
309.4 
±76.9*** 
211.4 
±28.9***
a
 
138.5 
±44.9***
ab
 
<.001 
SHBG, nmol/L 
44.0 
±17.9 
27.3 
±9.0
a
 
35.9 
±11.2
ab
 
<.001 46.5 ±19.0*** 25.2 ±7.6**
a
 38.2 ±14.5
ab
 <.001 
LH, U/L 
5.7 
±3.0 
4.7 
±2.0
a
 
4.7 
±2.0 
<.001 6.0 ±3.6*** 4.5 ±1.8
a
 4.0 ±1.8
a
 <.001 
FSH, U/L 7.3 6.0 6.4 
0.044 7.7 ±6.8*** 5.8 ±3.6
a
 5.9 ±3.5 0.008 
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±5.9 ±3.7 ±4.3 
Decreased 
morning 
erections, 
n(%) 
596 
(32.5) 
30 
(31.6) 
14 
(36.8) 
0.834 586 (33.8)* 35 (38.0) 22 (59.5)
a
 0.004 
Decreased 
sexual 
thoughts, n(%) 
409 
(22.3) 
21 
(21.9) 
11 
(29.0) 
0.616 452 (25.8)** 27 (29.4) 17 (44.7) 0.026 
Erectile 
dysfunction, 
n(%) 
444 
(24.3) 
19 
(20.0) 
14 
(36.8) 
0.123 509 (30.2)*** 25 (27.5) 21 (56.8)
ab
 0.002 
Decreased 
vigorous 
activity, n(%) 
352 
(18.9) 
15 
(15.0) 
6 (15.8) 0.561 419 (23.2)*** 23 (24.5)* 12 (32.4) 0.406 
Limited 
walking, n(%) 
74 
(4.0) 
5 (5.0) 2 (5.4) 0.613 132 (7.3)*** 7 (7.5) 7 (18.9)
a
 0.030 
Inability to 
bend, n(%) 
78 
(4.2) 
4 (4.0) 3 (7.9) 0.416 85 (4.7) 5 (5.3) 3 (8.1) 0.480 
Fatigue, n(%) 
67 
(3.6) 
4 (4.0) 2 (5.3) 0.634 78 (4.3) 8 (8.3) 3 (7.9) 0.080 
Loss of 
energy, n(%) 
68 
(3.6) 
3 (3.0) 1 (2.6) 1.000 97 (5.3)** 5 (5.2) 5 (13.2) 0.110 
Sadness, n(%) 
65 
(3.5) 
2 (2.0) 0 (0) 0.657 69 (3.9) 3 (3.2) 1 (2.8) 1.000 
 
Data are expressed as mean±standard deviation for continuous variables or as number (percentage) for binary 
categorical variables. 
1. P-values were calculated using baseline parameters and either the analysis of variance (ANOVA) for 
continuous variables or chi-squared test for categorical variables. 
2. P-values were calculated using follow-up parameters and either the analysis of variance (ANOVA) for 
continuous variables or chi-squared test for categorical variables. 
3. Educated to less than a university degree level 
a = data differ significantly (p<0.05) from the PE group using the Tukey–Kramer test for continuous variables or 
the z-test for categorical variables with correction for multiple pairwise comparisons. 
b = data differ significantly (p<0.05) from the incident LNSH group using the Tukey–Kramer test for continuous 
variables or the z-test for categorical variables with correction for multiple pairwise comparisons 
*, **, *** Data differ significantly (p<0.05, p<0.01 and p<0.001 respectively) from baseline values within the same 
group when analysed using paired t-tests (for continuous variables) or the McNemar test (for categorical 
variables).  
Abbreviations: PE, Persistent Eugonadism; SH, Secondary Hypogonadism; CVD, CardioVascular Disease; SF-
36, Short-Form 36 Questionnaire; DSST, Digital Symbol Substitution Test; PASE, Physical Activity Scale for the 
Elderly; PPT, Physical Performance Test; BMI, Body Mass Index; FPG, Fasting Plasma Glucose concentration; 
HOMA-IR, HOmeostatic Model of Insulin Resistance; PSA, Prostate Specific Antigen concentration; Hb, 
Haemoglobin; T, serum Testosterone concentration; SHBG, Sex Hormone Binding Globulin concentration; LH, 
Luteinising Hormone concentration; FSH, Follicular Stimulating Hormone Concentration   
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Table 2. Predictors of change in gonadal status from eugonadal to incident secondary 
hypogonadism  
Predictor 
Odds ratio [95% confidence interval] 
Incident LNSH Incident LLSH 
Age 
(years) 
60-69  1.58 [0.69-3.60] 0.59 [0.17-2.00] 
50-59 1.62 [0.70-3.76] 0.93 [0.33-2.61] 
40-49            3.24 [1.40-7.47] ** 0.59[0.17-2.00] 
≥1 comorbidities 1.55 [0.93-2.60] 1.21 [0.55-2.63] 
BMI (kg/m2) 
25-30            2.12 [1.06-4.22] * 1.86 [0.60-5.81] 
≥30           4.18 [2.00-8.71] ***          5.85 [1.86-18.37] ** 
Chronic pain 0.66 [0.26-1.70] 0.28 [0.04-2.12] 
Current smoking 0.78 [0.41-1.45] 1.23 [0.48-3.12] 
Frequent alcohol intake 1.21 [0.70-2.09] 0.61 [0.23-1.62] 
Pre-degree education 0.85 [0.64-1.14] 1.05 [0.68-1.62] 
Living with partner 1.35 [0.91-1.98] 1.28 [0.73-2.26] 
PAS ≤78 1.18 [0.48-2.87] 1.57 [0.52-4.73] 
 
Multiple logistic regression analysis of incident secondary hypogonadal groups (using persistent eugonadism as 
referent) in relation to risk factors. Data are expressed as odds ratio ±95% confidence interval. BMI categories 
considered were, BMI: 25–30 (overweight  and BMI≥30 kg/m
2
 (obese).  
Referent categories for predictors included in the analysis: Age >70 years; No comorbidities; BMI <25 kg/m
2
; No 
chronic pain; No current smoking; Infrequent alcohol intake: alcohol intake for less than 5 days per week; 
Educated to a university degree level; No partner or not living together with a partner; PASE >78. 
Abbreviations: LNSH, low total testosterone/normal free testosterone secondary hypogonadism; LLSH, low total 
testosterone/low free testosterone secondary hypogonadism; BMI, Body Mass Index; PASE, Physical Activity 
Scale for the Elderly 
Level of statistical significance is denoted by: * = p <0.05, ** = p <0.01 and *** = p <0.001   
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Table 3. Gonadal status transition in men with secondary hypogonadism (SH) at 
baseline  
  Baseline 
Total 
LNSH LLSH 
F
o
ll
o
w
-u
p
 
Eugonadism 80 14  
LNSH 70 10 217‡ 
LLSH 21 22  
Primary hypogonadism 2** 3** 
7 
Normal TT and Low FT - 2*‡ 
Total 173 51 224 
 
* These men were part of the original recovery from SH group (reference #9) and now excluded due to normal TT 
and low FT at follow-up. 
** These men are part of those excluded from the analytical group either in the present or in the previously 
published (reference #9) analytical groups due to primary hypogonadism at follow-up. 
‡ The sum of 217 men (with persistent SH or recovery from SH to eugonadism) and 2 men (with SH at baseline 
and normal TT and low FT at follow-up) makes altogether the 219 men in the original recovery from SH group 
(reference #9) 
Abbreviations: TT, total testosterone; FT, free testosterone; SH, secondary hypogonadism; LNSH, secondary 
hypogonadism with low total and normal free testosterone; LLSH, secondary hypogonadism with low total and 
low free testosterone.   
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